Risk factors and physiopathology of candidiasis

Revista Iberoamericana de Micologia

Volumn 14, Issue 1, 1997, Pages 6-13

  Senet, Jean Marcel ^a  

^a UNIVERSITÉ D'ANGERS   (France)

Author keywords

Candida; Candidiasis; Epidemiology; Immune deficiency; Opportunistic disease; Pathophysiology

Indexed keywords

EID: 0008776304     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (156)

1. Beck-Sague CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United Sates, 1980-1990. J Infect Dis 1993; 167: 1247-1251.
2. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-1530.
3. Fisherhoch SP, Hutwagner L. Opportunistic candidiasis: An epidemic of the 1980s. Clin Infect Dis 1995;21:897-904.
4. Muller J. The epidemiology of deep-seated, domestic mycoses. Mycoses 1994;37 (Suppl 2):1-7.
5. Koll B, Brown A. The changing epidemiology of infections at cancer hospitals Clin Infect Dis 1993;17(Suppl. 2) 322-328.
6. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20 115-125.
7. Pfaller MA Infection control opportunistic fungal infections-the increasing importance of Candida sp. Infect Control Hosp Epidemiol 1989;9:408-416.
8. Pfaller MA Epidemiology and control of fungal infections. Clin Infect Dis 1994,19 (Suppl. 1)S8-S13.
9. Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 1992;14 (Suppl. 1):S120-S125.
10. Wingard JR. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy Clin Infect Dis 1994;19 (Suppl. 1).S49-S53.
11. Boken D, Swindells S, et al. Fluconazole-resistant Candida albicans. Clin Infect Dis 1993;17:1018-1021.
12. Hazen KC New and emerging yeast patho- gens. Clin Microbiol Rev 1995;8:462.
13. Odds FC. Epidemiological shifts in opportunistic and nosocomial Candida infections. Mycological aspects. Int J Antimicrob Agents 1996;6:141-144.
14. Pfaller MA Nosocomial candidiasis: Emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996;22 (Suppl. 2) S89-S94
15. Romano F, Ribera G, Giuliano M A study of a hospital cluster of systemic candidosis using DNA typing methods. Epidemiol Infect 1994;112:393-398.
16. Vazquez JA, Sanchez V, Dmuchowski C, Dembry LM, Sobel JD, Zervos MJ. Nosocomial Acquisition of Candida albicans -an epidemiologic study J Infect Dis 1993; 168:195-201.
17. Rangel-Frausto M, Martin M, Saiman L. et al. High-prevalence of Candida species on hands care workers in surgical and neonatal intensive care units: a multicenter study 1994- 34th ICAAC. Poster #105.
18. Spinillo A, Capuzzo E, Nicola S, Baltaro F, Ferran A, Monaco A. The impact of oral contraception on vulvovaginal candidiasis. Contraception 1995;51:293-297.
19. Nohmi T, Abe S, Dobashi K, Tansho S, Yamaguchi H Suppression of anti-Candida activity of murine neutrophils by progesterone in vitro. A possible mechanism in pregnant women's vulnerability to vaginal candidiasis. Microbiol Immunol 1995;39:405-409.
20. Zhao X, Malloy PJ, Ardies CM, Feldman D Oestrogen-binding protein in Candida albicans Antibody development and cellular localization by electron immunocytochemistry. Microbiol-UK 1995,141 (Part 10):2685-2692.
21. Caticha O, Odell WD. Characterization and Purification of the chorionic gonadotropin-like protein binding site in Candida albicans. Endocrin Res 1994;20:1-19.
22. Reszel E, Mishra S, Mishra J, Mishra A, Pierson D. Stress, immunity and mucocutaneous candidiasis. J Osteopath Med 1993;7:26-28.
23. Martino P, Girmenia C, Micozzi A, et al Fungemia in patients with leukemia. Am J Med Sci 1993,306 225-232.
24. Swerdloff JN, Filler SG, Edwards JE. Severe candidal infections in neutropenic patients. Clin Infect Dis 1993;17 (Suppl. 2). S457-S467.
25. Jensen J, Warner T, Balish E. The role of phagocytic cells in resistance to disseminated candidiasis in granulocytopenic mice. J Infect Dis 1994;170:900-905.
26. Kirkpatrick CH. Chronic mucocutaneous candidiasis. J Am Acad Dermatol 1994; 31 (Suppl. 3, P2):S14-S17.
27. Segal E, Joseflev A. Induction of candidal vaginitis in diabetic mice and attempts to prevent the infection. J Med Vet Mycol 1995; 33:1-8
28. Kennedy MJ, Volz PA Effect of various antibiotics on gastrointestinal colonization and dissemination by Candida albicans. Sabouraudia: J Med Vet Mycol 1985;23:265-273
29. Vanwyk CW, Vanderbijl P, Stander I. Enhanced resistance to Candida albicans in mice during tetracycline administration South Afr J Sci 1995;91:140-141
30. Levine J, Dykoski RK, Janoff EN. Candida-associated diarrhea: A syndrome in search of credibility. Clin Infect Dis 1995;21:881-886.
31. Bernhardt H, Wellmer A, Zimmermann K, Knoke N. Growth of Candida albicans in normal and altered faecal flora in the model of continuous flow culture. Mycoses 1995,38: 265-270
32. Braun PC. Surface hydrophobicity enhances corticosterone incorporation in Candida albicans. Infect Immun 1994;62:4087-4090
33. Cavaillon JM Contribution of cytokines to inflammatory processes. Pathol Biol 1993;41:799-811
34. Nohmi T, Abe S, Tansho S, Yamaguchi H. Suppression of anti-Candida activity of murine and human neutrophils by glucocorticoids. Microbiol Immunol 1994;38:977-982.
35. Heidenreich S, Kubis T, Schmidt M, Fegeler W. Glucocorticoid-induced alterations of monocyte defense mechanisms against Candida albicans. Cell Immunol 1994,157:320-327.
36. Deslauriers N, Coulombs C, Carre B, Goulet JP Topical application of a corticosteroid destabilizes the host-parasite relationship in an experimental model of the oral carrier state of Candida albicans. FEMS Immunol Med Microbiol 1995,11.45-55.
37. Botas CM, Kurlat I, Young SWI, Sola A. Disseminated candidal infections and intravenous hydrocortisone in preterm infants. Pediatrics 1995,95:883-887.
38. Denning DW. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host J Antimicrob Chemother 1991;28.1-16
39. Chanock S. Evolving risk factors for infectious complications of cancer therapy Hematol Oncol Clin North Amer 1993;7: 771-793.
40. Ueta E, Osaki T, Yoneda K, Yamamoto T, Umazume M. Influence of inductive chemoradiotherapy on salivary polymorphonuclear leukocyte (SPMN) functions in oral cancer. J Oral Pathol Med 1994,23:418-422.
41. Mudad R, Vredenburgh J, Paulson EK, et al. A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis. Cancer 1994; 74:1360-1366.
42. Sandovskylosica H, Barrnea L, Segal E. Fatal systemic candidiasis of gastrointestinal origin - an experimental model in mice compromised by anti-cancer treatment. J Med Vet Mycol 1992;30:219-231.
43. Larner AJ. Hamilton MIR Infective complications of therapeutic gastric acid inhibition. Alimentar Pharmacol Ther 1994;8:579-584.
44. . 44. Hantala A, Niinikoski J, Lehtonen OP. Early Candida isolations in febrile patients after abdominal surgery. Scand J Infect Dis 1993; 25:479-485.
45. Pappo I, Polacheck I, Zmora O, Feigin E, Freund HR. Altered gut barrierfFunction to Candida during parenteral nutrition. Nutrition 1994;10:151-154.
46. Lecciones J, Lee J, Navarro E. et al Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992;14:875-883.
47. Raad I, Bodey G Infectious complications of indwelling vascular catheters. Clin Infect Dis 1992,15:197-210.
48. Stickler DJ, Mclean RJC. Biomaterials associated infections: The scale of the problem Cell Mater 1995,5:167-182.
49. Meyers J. Fungal infections in bone marrow transplant patients. Semin Oncol 1990;17: 10-13.
50. Morrison VA, Haake RJ, Weisdorf DJ. Non-candida fungal infections after bone marrow transplantation: Risk factors and outcome. Am J Med 1994;96:497-503.
51. Mccullough MJ, Ross BC, Dwyer BD, Reade PC. Genotype and phenotype of oral Candida albicans from patients infected with the human immunodeficiency virus. Microbiol-UK 1994;140:1195-1202.
52. Jones S, White G, Hunter PR. Increased phenotypic switching in strains of Candida albicans associated with invasive infections J Clin Microbiol 1994;32.2869-2870.
53. De Bernardis F, Adriani D, Lorenzini R, Pontieri E, Carruba G, Cassone A Filamentous growth and elevated vaginopathic potential of a nongerminative variant of Candida albicans expressing low virulence in systemic infection. Infect Immun 1993;61: 1500-1508.
54. Tronchin G, Bouchara JP, Robert R. Dynamic changes of the cell wall surface of Candida albicans associated with germination and adherence. Eur J Cell Biol 1989,50: 285-290.
55. Gow NAR, Perera THS. Sherwoodhigham J, Gooday GW, Gregory DW, Marshall D. Investigation of touch sensitive responses by hyphae of the human pathogenic fungus Candida albicans. Scan Micros 1994;8:705-710.
56. Critchley IA, Douglas LJ Role of glycosides as epithelial cell receptors for Candida albicans. J Gen Microbiol 1987,133.637-643.
57. Douglas LJ. Adhesion of Candida albicans to host surfaces. Candida and Candidamycosis 1991;50:43-47.
58. Tosh FD, Douglas LJ. Characterization of a fucoside-binding adhesin of Candida albicans Infect Immun 1992;60(11):4734-4739.
59. Calderone R, Wadsworth E. Adherence molecules of Candida albicans. J Microbiol Methods 1993;18:197-211.
60. Cameron BJ, Douglas LJ. Blood group glycolipids as epithelial cell receptors for Candida albicans Infect Immun 1996;64: 891-896.
61. Li RK, Cutler JE. Chemical Definition of an epitope/adhesin molecule on Candida albicans. J Biol Chem 1993,268:18293-18299
62. Kanbe T, Cutler JE Evidence for adhesin activity in the acid-stable moiety of the phosphomannoprotein cell wall complex of Candida albicans. Infect Immun 1994;62: 1662-1668.
63. Yu L, Lee KK, Sheth HB, et al. Fimbria-mediated adherence of Candida albicans to glycosphingolipid receptors on human buccal epithelial cells Infect Immun 1994;62.2843-2348
64. Lehrer N, Segal E Lis H, Gov I Effect of Candida albicans cell wall components on the adhesion of the fungus to human and murine vaginal mucosa. Mycopathologia 1988;102:115-121.
65. Bendel CM, Stsauver J, Carlson S, Hostetter MK Epithelial adhesion in yeast species: Correlation with surface expression of the integrin analog. J Infect Dis 1995.171: 1660-1663.
66. Edwards JE, Mayer CL, Filler SG, Wadsworth E, Calderone RA. Cell extracts of Candida albicans block adherence of the organisms to endothelial cells Infect Immun 1992;60:3087-3091
67. Klotz S, Harrison J, Misra R. Aggregated platelets enhance adherence of Candida yeasts to endothelium J Infect Dis 1989;160:669-677.
68. Filler SG, Ibe BO, Ibrahim AS, Ghannoum MA, Raj JU, Edwards JE. Mechanisms by which Candida albicans induces endothelial cell prostaglandin synthesis. Infect Immun 1994,62:1064-1069
69. Filler SG, Swerdloff JN, Hobbs C, Luckett PM. Penetration and damage of endothelial cells by Candida albicans. Infect Immun 1995;63:976-983
70. Calderone R, Diamond R, Senet JM, Warmington J, Filler S, Edwards JE. Host cell-fungal cell interactions J Med Vet Mycol 1994,32:151-168.
71. Klotz SA. Adherence of Candida albicans to endothelial cells is inhibited by prostaglandin I-2. infect Immun 1994;62:1497-1500.
72. Klotz SA, Hein RC, Smith RL, Rouse JB. The fibronectin adhesin of Candida albicans. Infect Immun 1994;62:4679-4681.
73. Penn C, Klotz SA. Binding of plasma fibronectin to Candida albicans occurs through the cell binding domain Microb Pathogen 1994;17:387-393
74. Santoni G, Gismondi A, Liu JH, et al Candida albicans expresses a fibronectin receptor antigenically related to alpha 5 beta 1 integrin. Microbiol-UK 1994;140:2971-2979.
75. Santoni G, Birarelli P, Hong LJ, Gamero A, Djeu JY, Piccoli M. An alpha 5 beta 1-like integrin receptor mediates the binding of less pathogenic Candida species to fibronectin. J Med Microbiol 1995,43:360-367.
76. Negre E, Vogel T, Levanon A, Guy R, Walsh TJ, Roberts DD. The collagen binding domain of fibronectin contains a high affinity binding site for Candida albicans. J Biol Chem 1994;269:22039-22045.
77. Bouchara J, Tronchin G, Annaix V, Robert R, Senet J Laminin receptors on Candida albicans germ tubes. Infect Immun 1990;58:48-54.
78. Lopez-Ribot JL, Casanova M, Monteagudo C, Sepulveda P, Martinez JP. Evidence for the presence of a high-affinity laminin receptor-like molecule on the surface of Candida albicans yeast cells. Infect Immun 1994,62 742-746.
79. Klotz SA, Smith RL. Gelatin fragments block adherence of Candida albicans to extracellular matrix proteins. Microbiol-UK 1995;141: 2681-2684.
80. Lopez-Ribot JL, Chaffin WL. Binding of the extracellular matrix component entactin to Candida albicans. Infect Immun 1994;62. 4564-4571
81. Gilmore B, Retsinas E, Lorenz J, Hostetter M An iC3b receptor on Candida albicans: structure, function and correlates for pathogenicity J Infect Dis 1988;157:38-46.
82. Alaei S, Larcher C. Ebenbichler C, Prodinger WM, Janatova J, Dierich MP Isolation and biochemical characterization of the iC3b receptor of Candida albicans Infect Immun 1993;61:1395-1399.
83. Hostetter MK. Adhesins and ligands involved in the interaction of Candida spp with epithelial and endothelial surfaces. Clin Microbiol Rev 1994;7:29-42
84. Calderone RA Linehan L, Wadsworth E, Sandberg AL. Identification of C3d receptors on Candida albicans Infect Immun 1988;56: 252-258
85. Wadsworth E, Prasad SC, Calderone R Analysis of mannoproteins from biastoconidia and hyphae of Candida albicans with a common epitope recognized by anti-complement receptor type-2 antibodies Infect Immun 1993;61.4675-4681.
86. Fukayama M, Wadsworth E, Calderone R Expression of the CSd-binding protein (CR2) from Candida albicans during experimental candidiasis as measured by lymphobiastogenesis. Infect Immun 1992;60.8-12
87. Franzke S, Calderone RA, Schaller K Isolation of avirulent clones of Candida albicans with reduced ability to recognize the CR2 ligand C3d. Infect Immun 1993;61: 2662-2669
88. Bouali A, Robert R, Tronchin G, Senet JM. Characterization of binding of human fibrinogen to the surface of germ-tubes and mycelium of Candida albicans J Gen Microbiol 1987;133:545-551.
89. Annaix V, Bouchara J, Tronchin G, Senet J, Robert R Structures involved in the binding of human fibrinogen to Candida albicans germ tubes. FEMS Microbiol Immunol 1990;64:147-154.
90. Robert R, Mahaza C, Marot-Leblond A, Tronchin G, Senet JM Binding of mouse fibrinogen to Candida albicans in vivo FEMS Microbiol Lett 1991;78:301-304
91. Casanova M, Lopez-Ribot JL, Monteagudo C, Llombartbosch A, Sentandreu R, Martinez JP. Identification of a 58-kilodalton cell surface fibrinogen-binding mannoprotein from Candida albicans. Infect Immun 1992;60:4221-4229.
92. Martinez JP, Lopez-Ribot JL, Chaffin WL. Heterogeneous surface distribution of the fibrinogen-binding protein on Candida albicans. Infect Immun 1994,62:709-712.
93. Tronchin G, Bouchara J, Robert R, Senet J. Adherence of Candida albicans germ tubes to plastic: ultrastructural and molecular studies of fibrilar adhesins. Infect Immun 1988,56:1987-1993.
94. Hawser SP, Douglas LJ. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun 1994;62: 915-921
95. Hawser SP, Douglas U. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 1995;39:2128-2131
96. Borg M, Ruchel R Expression of extracellular acid proteinase by proteolytic Candida spp. during experimental infection of oral mucosa Infect Immun 1978;56:626-631.
97. Rüchel R, De Bernardis F, Ray T, Sullivan P, Cole G. Candida acid proteinases. J Med Vet Mycol 1992;30 (Suppl.1):123-132.
98. White TC, Agabian N. Candida albicans secreted aspartyl proteinases: Isoenzyme pattern is determined by cell type, and levels are determined by environmental factors. J Bacteriol 1995;177:5215-5221
99. De Bernardis F, Cassone A, Sturtevant J, Calderone R. Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis. Infect immun 1995;63:1887-1892
100. De Bernardis F, Chiani P, Ciccozzi M, et al. Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infect Immun 1996;64:466-471.
101. Hoegl L, Ollert M, Korting HC The role of Candida albicans secreted aspartic proteinase in the development of candidoses. J Mol Med 1996;74:135-142
102. Hube B, Monod M, Schofield DA, Brown AJP, Gow NAR. Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans. Mol Microbiol 1994;14:87-99.
103. Kaminishi H, Miyaguchi H, Tamaki T, et al. Degradation of humoral host defense by Candida albicans proteinase. Infect Immun 1995;63:984-988.
104. Louie A, Dixon DM, Elmaghrabi EA, Burnett JW, Baltch AL, Smith RP Relationship between Candida albicans epidermolytic proteinase activity and virulence in mice. J Med Vet Mycol 1994;32:59-64.
105. Ollert MW, Wende C, Gorlich M. et al. Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients. J Clin Microbiol 1995;33 2543-2549
106. Nikai T, Okumura Y, Hasegawa Y, Uchiya K, Kamiya K, Sugihara H Isolation and characterization of fibrinogenase from Candida albicans NH-1 Int J Biochem 1993;25:1815-1822.
107. Ibrahim AS Mirbod F, Filler SG et al. Evidence implicating phospholipase as a virulence factor of Candida albicans Infect Immun 1995,63.1993-1998.
108. Hoffman MP, Haidaris CG. Analysis of Candida albicans adhesion to salivary mucin. Infect Immun 1993;61:1940-1949
109. Hoffman MP, Haidaris CG. Identification and characterization of a Candida albicans binding proteoglycan secreted from rat submandibular salivary glands. Infect Immun 1994;62:828-836
110. Rindum JL, Stenderup A, Holmstrup P Identification of Candida albicans types related to healthy and pathological oral mucosa. J Oral Pathol Med 1994;23.406-412
111. Mahaza C, Robert R, Miegeville M, Tronchin G, Senet JM. Candida albicans -platelet interaction - evidence for in vivo and in vitro, cell to cell attachment. In: Tumbay E (Ed.) Candida and Candidamycosis. New York. Plenum Press, 1991: 131-135
112. Mahaza C, Robert R, Senet JM. Candida albicans-platelet interaction: molecules involved in the adherence In: Tümbay E (Ed.) Candida and Candidamycosis New York, Plenum Press, 1991: 137-141.
113. Yeaman MR, Ibrahim AS, Edwards JE, Bayer AS, Ghannoum MA Thrombin-induced rabbit platelet microbicidal protein is fungicidal in vitro Antimicrob Agents Chemother 1993;37:546-553.
114. Yeaman MR, Soldan SS, Ghannoum MA, Edwards JE, Filler SG, Bayer AS. Resistance to platelet microbicidal protein results in increased seventy of experimental Candida albicans endocarditis Infect Immun 1996,64:1379-1384.
115. Ibrahim AS, Filler SG, Ghannoum MA, Edwards JE. Interferon-gamma protects endothelial cells from damage by Candida albicans J Infect Dis 1993;167 1467-1470
116. Martino P, Girmenia C, Venditti M. Candida colonization and systemic infection in neutropenic patients: A retrospective study. Cancer 1989;64:2030-2034.
117. Sohnle PG, Hahn BL, Wagner DK. Arrays of Candida albicans pseudohyphae that protect the organisms from neutrophil fungicidal mechanisms in experimental infections of mice. J Med Vet Mycol 1994,32:21-30
118. Steinshamn S, Bergh K, Waage A Effects of stem cell factor and granulocyte colony-stimulating factor on granulocyte recovery and Candida albicans-infection in granulocytopenic mice. J Infect Dis 1993; 168:1444-1448.
119. Hamood M, Bluche PF, Devroey C, Corazza F, Bujan W, Fondu P. Effects of recombinant human granulocyte-colony stimulating factor on neutropenic mice infected with Candida albicans: Acceleration of recovery from neutropenia and potentiation of anti-C. albicans resistance. Mycoses 1994, 37.93-99
120. Bellamy W, Wakabayashi H, Takase M, Kawase K, Shimamura S, Tomita M. Killing of Candida albicans by lactoferricin-B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med Microbiol Immunol 1993,182:97-105.
121. Nikawa H, Samaranayake LP, Tenovuo J, Pang KM, Hamada T. The fungicidal effect of human lactoferrin on Candida albicans and Candida krusei. Arch Oral Biol 1993;38: 1057-1063.
122. Diamond R, Clark R, Haudenschild C. Damage to Candida albicans hyphae and pseudohyphae by the myeloperoxidase system and oxydative products of neutrophil metabolism in vitro. J Clin Invest 1980;66: 908-917.
123. Stein DK, Malawista SE, Vanblaricom G, Wysong D, Diamond RD. Cytoplasts generate oxidants but require added neutrophil granule constituents for fungicidal activity against Candida albicans hyphae. J Infect Dis 1995;172:511-520.
124. McNamara M, Weissner J, Collins-Lech C, Hahn B, Sohnle P. Neutrophil death as a defence mechanism against Candida albicans infections Lancet 1988;2:1163-1165.
125. Kitz DJ, Stahl PD, Little JR. The Effect of a mannose binding protein on macrophage interactions with Candida albicans. Cell Mol Biol 1992,38 407-412
126. Limper AH, Standing JE. Vitronectin interacts with Candida albicans and augments organism attachment to the NR8383 macrophage cell line. Immunol Lett 1994;42.139-144
127. Szabo I, Guan LM, Rogers TJ. Modulation of macrophage phagocytic activity by cell wall components of Candida albicans. Cell Immunol 1995;164:182-138.
128. Blasi E, Pitzurra L, Puliti M, et al Differential susceptibility of yeast and hyphal forms of Candida albicans to macrophage-derived nitrogen-containing compounds Infect Immun 1995;63:1806-1809
129. Rementeria A, Garcia Tobalina R, Sevilla MJ. Nitric oxide-dependent killing of Candida albicans by murine peritoneal cells during an experimental infection. FEMS Immunol Med Microbiol 1995,11:157-162.
130. Vazqueztorres A, Jonescarson J, Balish E. Nitric oxide production does not directly increase macrophage candidacidal activity. Infect Immun 1995,63:1142-1144.
131. Watanabe K, Kagaya K, Yamada T, Fukazawa Y. Mechanism for candidacidal activity in macrophages activated by recombinant gamma-interferon Infect Immun 1991;59:521-528.
132. Steinshamn S, Waage A. Tumor necrosis factor and IL-6 in Candida albicans infection in normal and granulopenic mice. Infect Immun 1992;60:4003-4008.
133. Diamond R, Lyman C, Wysong D. Disparate effects of interferon-gamma and TNF-alpha on early neutrophil respiratory burst and fungicidal responses to Candida albicans hyphae in vitro. J Clin Invest 1991;87:711-720.
134. Stevenhagen A, Vanfurth R. Interferon-gamma activates the oxidative killing of Candida albicans by human granulocytes. Clin Exp immunol 1993;91:170-175.
135. Garner RE, Rubanowice K, Sawyer RT, Hudson JA. Secretion of TNF-alpha by alveolar macrophages in response to Candida albicans mannan. J Leukoc Biol 1994;55: 161-168.
136. Jouault T, Lepage G, Bernigaud A, et al. beta-1,2-linked oligomannosides from Candida albicans act as signals for tumor necrosis factor alpha production. Infect Immun 1995;63:2378-2381.
137. Castro M, Bjoraker JA, Rohrbach MS, Limper AH. Candida albicans induces the release of inflammatory mediators from human peripheral blood monocytes. Inflammation 1996;20.107-122.
138. Djeu JY, Liu JH, Wei S, et al. Function associated with IL-2 receptor-beta on human neutrophils - mechanism of activation of anti-fungal activity against Candida albicans by IL-2 J Immunol 1993;150:960-970.
139. Djeu J, Matsushima K, Oppenheim J, Shiotski K, Blanchard D. Functionnal activation of human neutrophils by recombinant monocyte-derived neutrophil chemotactic factor/IL-8. J Immunol 1990;144:2205-2210.
140. Wang M, Friedman H, Djeu J. Enhancement of human monocyte function against Candida albicans by the colony-stimulating factors (CSF): IL-3, granulocyte-macrophage CSF, and macrophage CSF J Immunol 1989;143.671-677.
141. Romani L, Howard DH. Mechanisms of resistance to fungal infections. Curr Opin Immunol 1995;7:517-523.
142. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, Mckenzie IFC Oxidative / reductive conjugation of mannan to antigen selects for T-1 or T-2 immune responses. Proc Natl Acad Sci USA 1995; 92: 10128-10132.
143. Mencacci A, Cenci E, Spaccapelo R, Tonnetti L Romani L. Rationale for cytokine and anti-cytokine therapy of Candida albicans infection. J Mycol Med 1995;5:25-30.
144. Mencacci A, Torosantucci A, Spaccapelo R, Romani L, Bistoni F, Cassons A. A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice. Infect Immun 1994;62:5353-5360.
145. Garner RE, Domer JE Lack of Effect of Candida albicans mannan on development of protective immune responses in experimental murine candidiasis Infect Immun 1994;62.738-741.
146. Franklyn K, Warmington J, Ott A, Ashman R. An immunodominant antigen of Candida albicans shows homology to the enzyme enolase. Immunol Cell Biol 1990;68:173-178.
147. Matthews RC. Candida albicans HSP-90 link between protective and auto Immunity. J Med Microbiol 1992;36:367-370.
148. Costantino PJ, Gare NF, Warmington JR. Humoral immune responses to systemic Candida albicans infection in inbred mouse strains. Immunol Cell Biol 1995;73:125-133.
149. Vudhichamnong K, Walker DM, Ryley HC. The effect of secretory immunoglobulin A on the in vitro adherence of the yeast Candida albicans to human oral epithelial cells. Arch Oral Biol 1982;27:617-621.
150. Coogan MM, Sweet SP, Challacombe SJ. Immunoglobulin A (IgA), IgA1, and IgA2 Antibodies to Candida albicans in whole and parotid saliva in human immunodeficiency virus infection and AIDS Infect Immun 1994; 62:892-896.
151. Umazume M, Ueta E, Osaki T. Reduced inhibition of Candida albicans adhesion by saliva from patients receiving oral cancer therapy. J Clin Microbiol 1995;33:432-439.
152. Swoboda RK, Bertram G, Budge S, Gooday GW, Gow NAR, Brown AJP. Structure and regulation of the HSP90 gene from the pathogenic fungus Candida albi- cans. Infect Immun 1995;63.4506-4514.
153. Lavalle R, Bromuro C, Ranucci L, Muller HM, Crisanti A, Cassone A. Molecular cloning and expression of a 70-kilodalton heat shock protein of Candida albicans Infect Immun 1995;63.4039-4045.
154. Maresca B, Kobayashi GS. Hsp70 in parasites: As an inducible protective protein and as an antigen Experientia 1994;50:1067-1074
155. Chakir J, Cote L, Coulombe C, Deslauriers N. Differential pattern of infection and immune response during experimental oral candidiasis in BALB/c and DBA/2 [H-2(d)] mice. Oral Microbiol Immunol 1994,9:88-94.
156. Jonescarson J, Vazqueztorres A, Vanderheyde HC, Warner T, Wagner RD, Balish E. Gamma delta T cell-induced nitric oxide production enhances resistance to mucosal candidiasis. Nature Med 1995;1:552-557.